<DOC>
	<DOCNO>NCT01384331</DOCNO>
	<brief_summary>Most Implanon user experience reduction frequency volume menstrual bleeding , substantial minority experience unpredictable frequent and/or prolong episode bleed . This double blind , placebo control , randomise study additional randomise non-blinded arm . Two hundred woman age 18-45 year , Implanon user prolong frequent breakthrough bleeding ( WHO definition ) recruit randomised 4 equal-sized treatment group 50 woman assign Marvelon 7 day 21 day , NuvaRing 21 day placebo . Recruited subject maintain daily menstrual diary chart minimum 90 day prior randomisation , enrol treatment phase provide meet one World Health Organization criterion prolong frequent bleeding Following initial 90 day record , eligible woman begin designated treatment day 1 next episode bleed spot . Analysis subsequent menstrual pattern begin day 1 bleeding/spotting episode continue 90 day .</brief_summary>
	<brief_title>New Treatments Troublesome Bleeding Implanon Users</brief_title>
	<detailed_description>This double blind , placebo control , randomise study additional randomise non-blinded arm . Two hundred woman age 18-45 year , Implanon user prolong frequent breakthrough bleeding ( WHO definition ) recruit randomised 4 equal-sized treatment group 50 woman assign Marvelon 7 day 21 day , NuvaRing 21 day placebo . Recruited subject maintain daily menstrual diary chart minimum 90 day prior randomisation , enrol treatment phase provide meet one World Health Organization criterion prolong frequent bleeding ( 90 day reference period one episode bleed and/or spot last &gt; 10 day , 4 bleeding/spotting episode ) . Randomisation perform computer generation random number table block ten , equal number four group . The medication pack sequentially number seal opaque envelope ( independent investigator ) . Following initial 90 day record , eligible woman begin designated treatment day 1 next episode bleed spot . Analysis subsequent menstrual pattern begin day 1 bleeding/spotting episode continue 90 day . Analysis pre-treatment menstrual pattern include 90 day immediately precede bleed episode treatment start . Women participate study approximately seven month depend bleed pattern . Data analysis : Data analyse intention treat basis , enter SPSS analyse prior break randomisation code . Frequency analyse undertaken demographic data mean ( SD ) compare check effectiveness randomisation scheme . Total number day spot , bleeding , bleed spot number episode pre post 90 day reference period enter .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Menstruation Disturbances</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<criteria>Healthy woman age 1845 use subdermal progestogenonly contraceptive implant experience frequent prolonged vaginal bleeding Willing keep menstrual diary 6 month Women currently previously Heart attack stroke Blood clot vein High blood pressure Severe liver kidney disease Blood pressure &gt; 135 mm systolic &gt; 85 mm diastolic Migraine aura Breast cancer genital cancer Severe chronic liver kidney disease Women know sensitivity ethinyl oestradiol , progestogens Women take phenytoin , carbamazepine phenobarbitol Women pregnant Women lactate Women unwilling keep daily menstrual diary otherwise unwilling follow study criterion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Implanon user</keyword>
	<keyword>Frequent bleeding</keyword>
	<keyword>Prolonged bleeding</keyword>
	<keyword>Comparison treatment</keyword>
	<keyword>Placebo control</keyword>
	<keyword>Randomly allocate tretment</keyword>
</DOC>